Browse
Search for other papers by Andres Elía in
Google Scholar
PubMed
Search for other papers by Leo Saldain in
Google Scholar
PubMed
Search for other papers by Silvia Lovisi in
Google Scholar
PubMed
Search for other papers by Paula Martínez Vazquez in
Google Scholar
PubMed
Search for other papers by Javier Burruchaga in
Google Scholar
PubMed
Search for other papers by Caroline A Lamb in
Google Scholar
PubMed
Search for other papers by Isabel Alicia Lüthy in
Google Scholar
PubMed
Search for other papers by Federico Diez in
Google Scholar
PubMed
Search for other papers by Natalie Z M Homer in
Google Scholar
PubMed
Search for other papers by Ruth Andrew in
Google Scholar
PubMed
Search for other papers by Paola Rojas in
Google Scholar
PubMed
Search for other papers by Claudia Lanari in
Google Scholar
PubMed
Progesterone receptors (PRs) are biomarkers used as prognostic and predictive factors in breast cancer, but they are still not used as therapeutic targets. We have proposed that the ratio between PR isoforms A and B (PRA and PRB) predicts antiprogestin responsiveness. The MIPRA trial confirmed the benefit of 200 mg mifepristone, administered to patients with tumors with a high PRA/PRB ratio, but dose-ranging has not been conducted. The aim of this study was to establish the plasma mifepristone levels of patients from the MIPRA trial, along with the resultant steroid profiles, and compare these with those observed in mifepristone-treated mice using therapeutic schemes able to induce the regression of experimental mammary carcinomas with high PRA/PRB ratios: 6 mg pellets implanted subcutaneously, or daily doses of 12 mg/kg body weight. The plasma levels of mifepristone and other 19 plasma steroids were measured by liquid chromatography–tandem mass spectometry. In mifepristone-treated mice, plasma levels were lower than those registered in mifepristone-treated patients (i.e. day 7 after treatment initiation, pellet-treated mice: 8.4 ± 3.9 ng/mL; mifepristone-treated patients: 300.3 ± 31.7 ng/mL (mean ± s.d.; P < 0.001)). The increase in corticoid related steroids observed in patients was not observed in mifepristone-treated mice. The increase in progesterone levels was the most significant side effect detected in mifepristone-treated mice after 14 or 21 days of treatment, probably due to an ovarian compensatory effect not observed in postmenopausal patients. We conclude that in future clinical trials using mifepristone, the possibility of lowering the standard daily dose of 200 mg should be considered.
Search for other papers by Robin Schürfeld in
Google Scholar
PubMed
Search for other papers by Christina Pamporaki in
Google Scholar
PubMed
Search for other papers by Mirko Peitzsch in
Google Scholar
PubMed
Search for other papers by Nada Rayes in
Google Scholar
PubMed
Search for other papers by Osama Sabri in
Google Scholar
PubMed
Center of Surgery, Department for Vascular Surgery, Diakonissen Hospital of Leipzig, Leipzig, Germany
Search for other papers by Silvio Rohm in
Google Scholar
PubMed
Search for other papers by Ronald Biemann in
Google Scholar
PubMed
Search for other papers by Benjamin Sandner in
Google Scholar
PubMed
Search for other papers by Anke Tönjes in
Google Scholar
PubMed
Search for other papers by Graeme Eisenhofer in
Google Scholar
PubMed
Measurements of plasma metanephrines and methoxytyramine provide a sensitive test for diagnosis of pheochromocytoma/paraganglioma. False-positive results remain a problem, particularly in patients taking norepinephrine reuptake-blocking drugs. Therefore, in this retrospective observational study, we measured plasma metanephrines and methoxytyramine in 61 patients taking norepinephrine reuptake blockers (tricyclic antidepressants or serotonin–norepinephrine reuptake inhibitors) and 17 others taking selective serotonin reuptake inhibitors, all without pheochromocytoma/paraganglioma. We highlight a singular case with strongly elevated plasma normetanephrine and methoxytyramine concentrations associated with norepinephrine reuptake blockade. Data were compared to results from 252 and 1804 respective patients with and without tumors. Plasma normetanephrine was 40% higher (P < 0.0001) in patients on norepinephrine reuptake blockers and methoxytyramine was 127% higher (P = 0.0062) in patients taking tricyclic antidepressants compared to patients not taking uptake blockers and without tumors. The corresponding false-positive rates rose (P < 0.0001) from 4.8% to 23.0% for normetanephrine and from 0.9% to 28.6% for methoxytyramine. Selective serotonin reuptake inhibitors did not increase plasma concentrations of metabolites. In the highlighted case, plasma normetanephrine and methoxytyramine were elevated more than six times above upper reference limits. A pheochromocytoma/paraganglioma, however, was excluded by functional imaging. All biochemical test results normalized after discontinuation of norepinephrine reuptake blockers. These findings clarify that norepinephrine reuptake blockers usually result in mild elevations of normetanephrine and methoxytyramine that, nevertheless, significantly increase the number of false-positive results. There can, however, be exceptions where increases in normetanephrine and methoxytyramine reach pathological levels. Such exceptions may reflect failure of centrally mediated sympathoinhibition that normally occurs with the norepinephrine reuptake blockade.
Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA
Search for other papers by Claire K Mulvey in
Google Scholar
PubMed
Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA
Search for other papers by Alan Paciorek in
Google Scholar
PubMed
Search for other papers by Farhana Moon in
Google Scholar
PubMed
Search for other papers by Paige Steiding in
Google Scholar
PubMed
Search for other papers by Brandon Shih in
Google Scholar
PubMed
Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA
Search for other papers by Matthew A Gubens in
Google Scholar
PubMed
Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA
Search for other papers by Li Zhang in
Google Scholar
PubMed
Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA
Search for other papers by Emily K Bergsland in
Google Scholar
PubMed
Search for other papers by Iona Cheng in
Google Scholar
PubMed
Lung neuroendocrine tumors (NETs) have few known predictors of survival. We investigated associations of sociodemographic, clinicopathologic, and treatment factors with overall survival (OS) and lung cancer-specific survival (LCSS) for incident lung NET cases (typical or atypical histology) in the California Cancer Registry (CCR) from 1992 to 2019. OS was estimated with the Kaplan–Meier method and compared by sociodemographic and disease factors univariately with the log-rank test. We used sequential Cox proportional hazards regression for multivariable OS analysis. LCSS was estimated using Fine-Gray competing risks regression. There were 6038 lung NET diagnoses (5569 typical, 469 atypical carcinoid); most were women (70%) and non-Hispanic White (73%). In our multivariable model, sociodemographic factors were independently associated with OS, with better survival for women (hazard ratio (HR) 0.62, 95% confidence interval (CI) 0.57–0.68, P < 0.001), married (HR 0.76, 95% CI 0.70–0.84, P < 0.001), and residents of high socioeconomic status (SES) neighborhoods (HRQ5vsQ1 0.73, 95% CI 0.62–0.85, P < 0.001). Compared to cases with private insurance, OS was worse for cases with Medicare (HR 1.24, 95% CI 1.10–1.40, P < 0.001) or Medicaid/other public insurance (HR 1.45, 95% CI 1.24–1.68, P < 0.001). In our univariate model, non-Hispanic Black Californians had worse OS than other racial/ethnic groups, but differences attenuated after adjusting for stage at diagnosis. In our LCSS models, we found similar associations between sex and marital status on survival, but no differences in outcomes by SES or insurance. By race/ethnicity, American Indian cases had worse LCSS. In summary, beyond disease-related and treatment variables, sociodemographic factors were independently associated with survival in lung NETs.
Department of Molecular and Translational Medicine, Division of Biology and Genetics, University of Brescia, Brescia, Italy
Search for other papers by Chiara Alessandra Cella in
Google Scholar
PubMed
Metal Targeted Therapy & Immunology lab, Childrens’ cancer institute, Sydney, NSW, Australia
Search for other papers by Riccardo Cazzoli in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Search for other papers by Giuseppina De Petro in
Google Scholar
PubMed
Search for other papers by Germano Gaudenzi in
Google Scholar
PubMed
Search for other papers by Silvia Carra in
Google Scholar
PubMed
Search for other papers by Mauro Romanenghi in
Google Scholar
PubMed
Search for other papers by Francesca Spada in
Google Scholar
PubMed
Search for other papers by Ilaria Grossi in
Google Scholar
PubMed
Search for other papers by Isabella Pallavicini in
Google Scholar
PubMed
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
Search for other papers by Saverio Minucci in
Google Scholar
PubMed
Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
Search for other papers by Giovanni Vitale in
Google Scholar
PubMed
Neuroendocrine tumors (NETs) are highly vascularized malignancies in which angiogenesis may entail cell proliferation and survival. Among the emerging compounds with antivascular properties, cabozantinib (CAB) appeared promising. We analyzed the antitumor activity of CAB against NETs utilizing in vitro and in vivo models. For cell cultures, we used BON-1, NCI-H727 and NCI-H720 cell lines. Cell viability was assessed by manual count coupled with quantification of cell death, performed through fluorescence-activated cell sorting analysis as propidium iodide exclusion assay. In addition, we investigated the modulation of the antiapoptotic myeloid cell leukemia 1 protein under CAB exposure, as a putative adaptive pro-survival mechanism, and compared the responses with sunitinib. The activity of CAB was also tested in mouse and zebrafish xenograft tumor models. Cabozantinib showed a dose-dependent and time-dependent effect on cell viability and proliferation in human NET cultures, besides a halting of cell cycle progression for endoduplication, never reported for other tyrosine kinase inhibitors. In a transplantable zebrafish model, CAB drastically inhibited NET-induced angiogenesis and migration of implanted cells through the embryo body. CAB showed encouraging activity in NETs, both in vitro and in vivo models. On this basis, we envisage future research to further investigate along these promising lines.
Search for other papers by Paola De Marco in
Google Scholar
PubMed
Search for other papers by Enrica Romeo in
Google Scholar
PubMed
Search for other papers by Adele Vivacqua in
Google Scholar
PubMed
Search for other papers by Roberta Malaguarnera in
Google Scholar
PubMed
Search for other papers by Sergio Abonante in
Google Scholar
PubMed
Search for other papers by Francesco Romeo in
Google Scholar
PubMed
Search for other papers by Vincenzo Pezzi in
Google Scholar
PubMed
Search for other papers by Antonino Belfiore in
Google Scholar
PubMed
Search for other papers by Marcello Maggiolini in
Google Scholar
PubMed
Search for other papers by Walid Zeyghami in
Google Scholar
PubMed
Search for other papers by Marie-Louise Uhre Hansen in
Google Scholar
PubMed
Search for other papers by Kathrine Kronberg Jakobsen in
Google Scholar
PubMed
Search for other papers by Christian Groenhøj in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Clinical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Clinical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Christian von Buchwald in
Google Scholar
PubMed
Search for other papers by Christoffer Holst Hahn in
Google Scholar
PubMed
Thyroid cancer (TC) represents the most common endocrine malignant tumor. Liquid biopsy has been suggested as a new and accurate biomarker in cancer. This systematic review analyzes the existing literature on circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA integrity index (cfDI), and their potential as biomarkers for TC, including the subtypes: differentiated (papillary and follicular), medullary, and anaplastic. A systematic search was performed in PubMed, Embase, and Cochrane databases for published articles in English between 1 January 1970 and 6 September 2022 (PROSPERO: CRD42022358592). The literature search generated a total of 635 articles. In total, 36 articles were included (patients = 2566). Four studies reported that higher levels of CTCs were associated with metastases and worse prognosis. Nineteen studies found the presence of mutated ctDNA in TC patients. The diagnostic accuracy in detecting BRAFV600E as ctDNA was determined in 11 studies regarding papillary TC. The pooled sensitivity, specificity, and diagnostic odds ratio were estimated at 56% (95% CI 36–74), 91% (95% CI 84–95) and 12 (95% CI 4.09–33.11), respectively. Four studies concluded that the cfDI was higher in patients with TC compared to benign thyroid lesions and healthy controls. The detection of CTCs, ctDNA, and cfDI may have a potential prognostic value in TC in relation to diagnosis, disease progression, and treatment efficacy. Despite the promising potential of CTCs, ctDNA, and cfDI in TC management, limitations hinder direct comparison and generalization of findings. Standardized methodologies, larger patient cohorts, and a consensus on relevant markers are needed to validate their clinical applicability and enhance TC management.
Search for other papers by Barbora Bulanova Pekova in
Google Scholar
PubMed
Search for other papers by Vlasta Sykorova in
Google Scholar
PubMed
Search for other papers by Karolina Mastnikova in
Google Scholar
PubMed
Search for other papers by Eliska Vaclavikova in
Google Scholar
PubMed
Search for other papers by Jitka Moravcova in
Google Scholar
PubMed
Search for other papers by Petr Vlcek in
Google Scholar
PubMed
Search for other papers by Lucie Lancova in
Google Scholar
PubMed
Search for other papers by Petr Lastuvka in
Google Scholar
PubMed
Search for other papers by Rami Katra in
Google Scholar
PubMed
Search for other papers by Petr Bavor in
Google Scholar
PubMed
Search for other papers by Daniela Kodetova in
Google Scholar
PubMed
Search for other papers by Martin Chovanec in
Google Scholar
PubMed
Search for other papers by Jana Drozenova in
Google Scholar
PubMed
Search for other papers by Radoslav Matej in
Google Scholar
PubMed
Search for other papers by Jaromir Astl in
Google Scholar
PubMed
Search for other papers by Jiri Hlozek in
Google Scholar
PubMed
Search for other papers by Petr Hrabal in
Google Scholar
PubMed
Search for other papers by Josef Vcelak in
Google Scholar
PubMed
Search for other papers by Bela Bendlova in
Google Scholar
PubMed
Thyroid cancer is associated with a broad range of different mutations, including RET (rearranged during transfection) fusion genes. The importance of characterizing RET fusion-positive tumors has recently increased due to the possibility of targeted treatment. The aim of this study was to identify RET fusion-positive thyroid tumors, correlate them with clinicopathological features, compare them with other mutated carcinomas, and evaluate long-term follow-up of patients. The cohort consisted of 1564 different thyroid tissue samples (including 1164 thyroid carcinoma samples) from pediatric and adult patients. Samples were analyzed for known driver mutations occurring in thyroid cancer. Negative samples were subjected to extensive RET fusion gene analyses using next-generation sequencing and real-time PCR. RET fusion genes were not detected in any low-risk neoplasm or benign thyroid tissue and were detected only in papillary thyroid carcinomas (PTCs), in 113/993 (11.4%) patients, three times more frequently in pediatric and adolescent patients (29.8%) than in adult patients (8.7%). A total of 20 types of RET fusions were identified. RET fusion-positive carcinomas were associated with aggressive tumor behavior, including high rates of lymph node (75.2%) and distant metastases (18.6%), significantly higher than in NTRK fusion, BRAF V600E and RAS-positive carcinomas. Local and distant metastases were also frequently found in patients with microcarcinomas positive for the RET fusions. ’True recurrences’ occurred rarely (2.4%) and only in adult patients. The 2-, 5-, 10-year disease-specific survival rates were 99%, 96%, and 95%, respectively. RET fusion-positive carcinomas were associated with high invasiveness and metastatic activity, but probably due to intensive treatment with low patient mortality.
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Search for other papers by Parvin Yenki in
Google Scholar
PubMed
Search for other papers by Satyam Bhasin in
Google Scholar
PubMed
Search for other papers by Liang Liu in
Google Scholar
PubMed
Search for other papers by Noushin Nabavi in
Google Scholar
PubMed
Search for other papers by Chi Wing Cheng in
Google Scholar
PubMed
Search for other papers by Kevin J Tam in
Google Scholar
PubMed
Search for other papers by James W Peacock in
Google Scholar
PubMed
Search for other papers by Hans H Adomat in
Google Scholar
PubMed
Search for other papers by Tabitha Tombe in
Google Scholar
PubMed
Search for other papers by Ladan Fazli in
Google Scholar
PubMed
Search for other papers by Larissa Ivanova in
Google Scholar
PubMed
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Search for other papers by Christopher Dusek in
Google Scholar
PubMed
Search for other papers by Shahram Khosravi in
Google Scholar
PubMed
Search for other papers by Emma S Tomlinson Guns in
Google Scholar
PubMed
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Search for other papers by Yuzhuo Wang in
Google Scholar
PubMed
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Search for other papers by Ralph Buttyan in
Google Scholar
PubMed
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Search for other papers by Martin E Gleave in
Google Scholar
PubMed
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Search for other papers by Christopher J Ong in
Google Scholar
PubMed
Intratumoral androgen biosynthesis contributes to castration-resistant prostate cancer progression in patients treated with androgen deprivation therapy. The molecular mechanisms by which castration-resistant prostate cancer acquires the capacity for androgen biosynthesis to bypass androgen deprivation therapy are not entirely known. Here, we show that semaphorin 3C, a secreted signaling protein that is highly expressed in castration-resistant prostate cancer, can promote steroidogenesis by altering the expression profile of key steroidogenic enzymes. Semaphorin 3C not only upregulates enzymes required for androgen synthesis from dehydroepiandrosterone or de novo from cholesterol but also simultaneously downregulates enzymes involved in the androgen inactivation pathway. These changes in gene expression correlate with increased production of androgens induced by semaphorin 3C in prostate cancer model cells. Moreover, semaphorin 3C upregulates androgen synthesis in LNCaP cell-derived xenograft tumors, likely contributing to the enhanced in vivo tumor growth rate post castration. Furthermore, semaphorin 3C activates sterol regulatory element-binding protein, a transcription factor that upregulates enzymes involved in the synthesis of cholesterol, a sole precursor for de novo steroidogenesis. The ability of semaphorin 3C to promote intratumoral androgen synthesis may be a key mechanism contributing to the reactivation of the androgen receptor pathway in castration-resistant prostate cancer, conferring continued growth under androgen deprivation therapy. These findings identify semaphorin 3C as a potential therapeutic target for suppressing intratumoral steroidogenesis.
Search for other papers by Roberto Olmos in
Google Scholar
PubMed
Search for other papers by José Miguel Domínguez in
Google Scholar
PubMed
Search for other papers by Sergio Vargas-Salas in
Google Scholar
PubMed
Search for other papers by Lorena Mosso in
Google Scholar
PubMed
Search for other papers by Carlos E Fardella in
Google Scholar
PubMed
Search for other papers by Gilberto González in
Google Scholar
PubMed
Search for other papers by René Baudrand in
Google Scholar
PubMed
Search for other papers by Francisco Guarda in
Google Scholar
PubMed
Search for other papers by Felipe Valenzuela in
Google Scholar
PubMed
Search for other papers by Eugenio Arteaga in
Google Scholar
PubMed
Search for other papers by Pablo Forenzano in
Google Scholar
PubMed
Search for other papers by Flavia Nilo in
Google Scholar
PubMed
Search for other papers by Nicole Lustig in
Google Scholar
PubMed
Search for other papers by Alejandra Martínez in
Google Scholar
PubMed
Search for other papers by José M López in
Google Scholar
PubMed
Search for other papers by Francisco Cruz in
Google Scholar
PubMed
Search for other papers by Soledad Loyola in
Google Scholar
PubMed
Search for other papers by Augusto Leon in
Google Scholar
PubMed
Search for other papers by Nicolás Droppelmann in
Google Scholar
PubMed
Search for other papers by Pablo Montero in
Google Scholar
PubMed
Search for other papers by Francisco Domínguez in
Google Scholar
PubMed
Search for other papers by Mauricio Camus in
Google Scholar
PubMed
Search for other papers by Antonieta Solar in
Google Scholar
PubMed
Search for other papers by Pablo Zoroquiain in
Google Scholar
PubMed
Search for other papers by Juan Carlos Roa in
Google Scholar
PubMed
Search for other papers by Estefanía Muñoz in
Google Scholar
PubMed
Search for other papers by Elsa Bruce in
Google Scholar
PubMed
Search for other papers by Rossio Gajardo in
Google Scholar
PubMed
Search for other papers by Giovanna Miranda in
Google Scholar
PubMed
Search for other papers by Francisco Riquelme in
Google Scholar
PubMed
Search for other papers by Natalia Mena in
Google Scholar
PubMed
Search for other papers by Hernán E González in
Google Scholar
PubMed
Molecular testing contributes to improving the diagnosis of indeterminate thyroid nodules (ITNs). ThyroidPrint® is a ten-gene classifier aimed to rule out malignancy in ITN. Post-validation studies are necessary to determine the real-world clinical benefit of ThyroidPrint® in patients with ITN. A single-center, prospective, noninterventional clinical utility study was performed, analyzing the impact of ThyroidPrint® in the physicians’ clinical decisions for ITN. Demographics, nodule characteristics, benign call rates (BCRs), and surgical outcomes were measured. Histopathological data were collected from surgical biopsies of resected nodules. Of 1272 fine-needle aspirations, 109 (8.6%) were Bethesda III and 135 (10.6%) were Bethesda IV. Molecular testing was performed in 155 of 244 ITN (63.5%), of which 104 were classified as benign (BCR of 67.1%). After a median follow-up of 15 months, 103 of 104 (99.0%) patients with a benign ThyroidPrint® remained under surveillance and one patient underwent surgery which was a follicular adenoma. Surgery was performed in all 51 patients with a suspicious for malignancy as per ThyroidPrint® result and in 56 patients who did not undergo testing, with a rate of malignancy of 70.6% and 32.1%, respectively. A higher BCR was observed in follicular lesion of undetermined significance (87%) compared to atypia of undetermined significance (58%) (P < 0.05). False-positive cases included four benign follicular nodules and six follicular and four oncocytic adenomas. Our results show that, physicians chose active surveillance instead of diagnostic surgery in all patients with a benign ThyroidPrint® result, reducing the need for diagnostic surgery in 67% of patients with preoperative diagnosis of ITN.